Needham & Company LLC started coverage on shares of Agilent Technologies (NYSE:A) in a report released on Friday, Benzinga reports. The brokerage issued a buy rating and a $77.00 price target on the medical research company’s stock.
A number of other research firms have also recently issued reports on A. Barclays decreased their price target on shares of Agilent Technologies from $78.00 to $76.00 and set an equal weight rating for the company in a report on Wednesday, October 9th. Stifel Nicolaus initiated coverage on shares of Agilent Technologies in a report on Thursday, November 14th. They issued a hold rating and a $85.00 price target for the company. UBS Group raised their price target on shares of Agilent Technologies from $82.00 to $87.00 and gave the stock a neutral rating in a report on Tuesday, November 26th. Finally, JPMorgan Chase & Co. raised their price target on shares of Agilent Technologies from $85.00 to $90.00 and gave the stock an overweight rating in a report on Tuesday, November 26th. Six research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company presently has an average rating of Buy and a consensus price target of $83.25.
Agilent Technologies stock opened at $84.57 on Friday. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.53 and a quick ratio of 1.21. Agilent Technologies has a 1-year low of $64.09 and a 1-year high of $86.35. The firm has a market capitalization of $26.66 billion, a P/E ratio of 27.19, a price-to-earnings-growth ratio of 2.02 and a beta of 1.42. The company’s 50-day moving average is $82.40 and its 200 day moving average is $75.51.
Agilent Technologies (NYSE:A) last issued its earnings results on Monday, November 25th. The medical research company reported $0.89 EPS for the quarter, topping the Zacks’ consensus estimate of $0.86 by $0.03. The business had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.33 billion. Agilent Technologies had a net margin of 20.74% and a return on equity of 20.13%. The company’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.81 EPS. Research analysts anticipate that Agilent Technologies will post 3.41 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 22nd. Shareholders of record on Tuesday, December 31st will be issued a $0.18 dividend. This represents a $0.72 dividend on an annualized basis and a yield of 0.85%. The ex-dividend date is Monday, December 30th. This is an increase from Agilent Technologies’s previous quarterly dividend of $0.16. Agilent Technologies’s payout ratio is currently 23.15%.
In other news, SVP Dominique Grau sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $82.85, for a total value of $1,242,750.00. Following the transaction, the senior vice president now owns 97,498 shares in the company, valued at $8,077,709.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michael R. Mcmullen sold 24,636 shares of the firm’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $80.00, for a total value of $1,970,880.00. Following the completion of the transaction, the chief executive officer now owns 332,121 shares in the company, valued at approximately $26,569,680. The disclosure for this sale can be found here. In the last three months, insiders have sold 75,652 shares of company stock valued at $6,219,246.
Hedge funds have recently bought and sold shares of the company. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lifted its stake in Agilent Technologies by 81.0% during the second quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 157,403 shares of the medical research company’s stock worth $11,753,000 after purchasing an additional 70,426 shares during the last quarter. HighTower Advisors LLC lifted its stake in Agilent Technologies by 1,183.0% during the second quarter. HighTower Advisors LLC now owns 122,800 shares of the medical research company’s stock worth $9,132,000 after purchasing an additional 113,229 shares during the last quarter. Pinebridge Investments L.P. bought a new stake in Agilent Technologies during the second quarter worth about $58,000. Pershing Square Capital Management L.P. bought a new stake in Agilent Technologies during the third quarter worth about $223,461,000. Finally, Doyle Wealth Management bought a new stake in Agilent Technologies during the second quarter worth about $37,000.
Agilent Technologies Company Profile
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.
Read More: What does a neutral rating on stocks mean?
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.